Literature DB >> 4042093

An efficient design for phase III studies of combination chemotherapies.

S S Ellenberg, M A Eisenberger.   

Abstract

Mesh：

Year:  1985        PMID： 4042093

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  14 in total

Review 1.  A review of phase 2-3 clinical trial designs.

Authors:  Peter F Thall
Journal:  Lifetime Data Anal       Date:  2007-09-02       Impact factor: 1.588

2.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

3.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

4.  Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Authors:  Stuart A Grossman; Karisa C Schreck; Karla Ballman; Brian Alexander
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

5.  Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

6.  Sequential design of phase II-III cancer trials.

Authors:  Tze Leung Lai; Philip W Lavori; Mei-Chiung Shih
Journal:  Stat Med       Date:  2012-03-16       Impact factor: 2.373

7.  Comparison of futility monitoring guidelines using completed phase III oncology trials.

Authors:  Qiang Zhang; Boris Freidlin; Edward L Korn; Susan Halabi; Sumithra Mandrekar; James J Dignam
Journal:  Clin Trials       Date:  2016-09-22       Impact factor: 2.486

Review 8.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

Review 10.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.